Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Directorate Change

29 Nov 2018 10:37

RNS Number : 9093I
Maven Income & Growth VCT PLC
29 November 2018
 

Maven Income and Growth VCT PLC (the Company)

 

Directorate Changes

 

As announced on 26 September 2018, alongside the publication of the Prospectus for the Offer for Subscription, the Board now confirms that Fiona Wollocombe will resign as a Non-executive Director of the Company with effect from 24 January 2019. Mrs Wollocombe has been a Director of the Company since 20 May 2004, serving as its Chairman from 7 July 2005 until 8 July 2010, and the Board wishes to record its gratitude for the significant contribution Fiona made during her time in office and extends to her its best wishes for the future.

 

The Board is also pleased to announce the appointments of Dr Alison Fielding and Dr Andrew Harrington as Non-executive Directors, each with effect from 1 January 2019. Both of these new Directors will also serve on the Company's Audit, Management Engagement, Nomination, Risk and Remuneration Committees, and will stand for election by Shareholders at the Annual General Meeting to be held in July 2019

 

Dr Fielding is an experienced entrepreneur, senior executive and non-executive director, with a track record of leading strategy within both large and small organisations to set direction, evaluate options, implement plans and drive performance. She is currently a venture partner at IP Group plc, with her role there including two non-executive directorships with portfolio companies; Perachem Holdings plc, of which she is chairman, and Getech Group plc, where she chairs the audit committee.

 

Alison has held a number of other non-executive roles and her other current appointments include non-executive directorships of Nanoco Group plc and Queen Mary Innovation Limited, and serving as a trustee of the Royal Voluntary Service and the Carnegie Trust for the Universities of Scotland.

 

Dr Harrington is co-owner of AHV Associates LLP, which was formed in 2001 and works alongside management teams and shareholders across many sectors to advise on transactions, such as the purchase or sale of companies and capital raising.

 

Andrew was previously founder and chief executive of Nextcall Telecom, a business backed by venture and private investor capital, before which he was managing director at Salomon Brothers, where he advised on investment, IPOs, secondary public market offerings and mergers & acquisitions.

 

In relation to both of these new appointments, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

 

Maven Capital Partners UK LLP

Secretary

29 November 2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGGQWGUPRGUB
Date   Source Headline
2nd Jun 20264:19 pmRNSAnnual Financial Report
1st May 20263:20 pmRNSTransaction in Own Shares
30th Apr 20265:09 pmRNSTransaction in Own Shares
30th Apr 202610:51 amRNSAdmission of Further Securities to Trading
29th Apr 202612:23 pmRNSIssue of Equity
27th Apr 20263:29 pmRNSUnaudited Net Asset Value and Dividend Declaration
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:17 amRNSAdmission of Further Securities to Trading
14th Apr 202611:06 amRNSIssue of Equity
8th Apr 20269:27 amRNSAdmission of Further Securities to Trading
25th Mar 202610:49 amRNSAdmission of Further Securities to Trading
24th Mar 202612:08 pmRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
29th Jan 20264:54 pmRNSTransaction in Own Shares
21st Jan 202611:01 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:39 amRNSIssue of Equity
15th Jan 202610:27 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 20269:50 amRNSIssue of Equity
14th Jan 20262:33 pmRNSUnaudited NAV - Dividend Investment Scheme
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:39 pmRNSResult of General Meeting
29th Oct 20257:00 amRNSHalf-year Report
16th Oct 20254:43 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:06 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:12 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:33 pmRNSTransaction in Own Shares
18th Jul 202510:08 amRNSIssue of Equity - Dividend Investment Scheme
16th Jul 20257:08 amRNSStatement re Offer for Subscription
11th Jul 20253:56 pmRNSStatement re Dividend Investment Scheme
11th Jul 20252:58 pmRNSStatement re Unaudited NAV and Interim Dividend
10th Jul 20252:32 pmRNSResult of AGM
28th May 20254:18 pmRNSAnnual Financial Report
7th May 20254:35 pmRNSTransaction in Own Shares
6th May 202511:51 amRNSIssue of Equity
25th Apr 20254:19 pmRNSUnaudited NAV and Proposed Final Dividend
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:15 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:02 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:23 pmRNSUnaudited Net Asset Value
29th Jan 20254:35 pmRNSTransaction in Own Shares
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202511:27 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.